Petrus Trust Company LTA Takes Position in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Petrus Trust Company LTA has acquired 6,272 shares of Jazz Pharmaceuticals, valued at approximately $779,000, indicating growing interest from institutional investors in the company.
• Despite a revenue of $1.05 billion, Jazz Pharmaceuticals reported an earnings per share (EPS) of ($8.25), which fell short of analysts' expectations, although the company anticipates an EPS of 4.800-5.600 for FY 2025.
• Multiple research analysts have recently rated Jazz Pharmaceuticals as a "buy," with price targets ranging from $152.00 to $202.00, reflecting positive sentiment in the market surrounding the stock.

Petrus Trust Company LTA purchased a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,272 shares of the specialty pharmaceutical company's stock, valued at approximately $779,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Dimensional Fund Advisors LP grew its stake in Jazz Pharmaceuticals by 14.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company's stock worth $289,066,000 after buying an additional 293,360 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Jazz Pharmaceuticals by 4.7% during the 1st quarter. JPMorgan Chase & Co. now owns 1,662,042 shares of the specialty pharmaceutical company's stock worth $206,343,000 after buying an additional 74,501 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its stake in Jazz Pharmaceuticals by 41.7% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company's stock worth $165,245,000 after buying an additional 391,660 shares during the last quarter. Vestal Point Capital LP grew its stake in Jazz Pharmaceuticals by 8.3% during the 4th quarter. Vestal Point Capital LP now owns 975,000 shares of the specialty pharmaceutical company's stock worth $120,071,000 after buying an additional 75,000 shares during the last quarter. Finally, Perpetual Ltd boosted its position in Jazz Pharmaceuticals by 60.2% during the 1st quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company's stock worth $118,212,000 after acquiring an additional 357,784 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on JAZZ shares. Deutsche Bank Aktiengesellschaft started coverage on Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target for the company. Morgan Stanley boosted their price objective on Jazz Pharmaceuticals from $162.00 to $163.00 and gave the stock an "overweight" rating in a research note on Thursday, August 28th. Needham & Company LLC reissued a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Royal Bank Of Canada lifted their target price on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a report on Thursday, August 28th. Finally, Zacks Research upgraded Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Fourteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $178.67.

Jazz Pharmaceuticals Stock Down 1.0%

Shares of Jazz Pharmaceuticals stock traded down $1.32 during midday trading on Tuesday, hitting $128.53. The company's stock had a trading volume of 574,857 shares, compared to its average volume of 713,676. The firm has a market capitalization of $7.80 billion, a P/E ratio of -19.10, a PEG ratio of 8.05 and a beta of 0.24. The stock has a 50-day simple moving average of $117.54 and a 200-day simple moving average of $116.81. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business's quarterly revenue was up 2.1% on a year-over-year basis. During the same period last year, the business earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, sell-side analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Insider Activity

In related news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total transaction of $771,720.00. Following the completion of the sale, the director directly owned 429,973 shares in the company, valued at approximately $55,303,127.26. This trade represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.